首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Studies of New Fused Benzazepine as Selective Dopamine D3 Receptor Antagonists Using 3D-QSAR Molecular Docking and Molecular Dynamics
【2h】

Studies of New Fused Benzazepine as Selective Dopamine D3 Receptor Antagonists Using 3D-QSAR Molecular Docking and Molecular Dynamics

机译:使用3D-QSAR分子对接和分子动力学研究新型融合的苯并ze庚因作为多巴胺D3受体选择性拮抗剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In recent years, great interest has been paid to the development of compounds with high selectivity for central dopamine (DA) D3 receptors, an interesting therapeutic target in the treatment of different neurological disorders. In the present work, based on a dataset of 110 collected benzazepine (BAZ) DA D3 antagonists with diverse kinds of structures, a variety of in silico modeling approaches, including comparative molecular field analysis (CoMFA), comparative similarity indices analysis (CoMSIA), homology modeling, molecular docking and molecular dynamics (MD) were carried out to reveal the requisite 3D structural features for activity. Our results show that both the receptor-based (Q2 = 0.603, R2ncv = 0.829, R2pre = 0.690, SEE = 0.316, SEP = 0.406) and ligand-based 3D-QSAR models (Q2 = 0.506, R2ncv =0.838, R2pre = 0.794, SEE = 0.316, SEP = 0.296) are reliable with proper predictive capacity. In addition, a combined analysis between the CoMFA, CoMSIA contour maps and MD results with a homology DA receptor model shows that: (1) ring-A, position-2 and R3 substituent in ring-D are crucial in the design of antagonists with higher activity; (2) more bulky R1 substituents (at position-2 of ring-A) of antagonists may well fit in the binding pocket; (3) hydrophobicity represented by MlogP is important for building satisfactory QSAR models; (4) key amino acids of the binding pocket are CYS101, ILE105, LEU106, VAL151, PHE175, PHE184, PRO254 and ALA251. To our best knowledge, this work is the first report on 3D-QSAR modeling of the new fused BAZs as DA D3 antagonists. These results might provide information for a better understanding of the mechanism of antagonism and thus be helpful in designing new potent DA D3 antagonists.
机译:近年来,人们对开发对中枢多巴胺(DA)D3受体具有高选择性的化合物非常感兴趣,该化合物是治疗各种神经系统疾病的有趣治疗靶标。在目前的工作中,基于110种收集的具有各种结构的苯并B庚因(BAZ)DA D3拮抗剂的数据集,多种计算机模拟方法,包括比较分子场分析(CoMFA),比较相似性指数分析(CoMSIA),进行了同源性建模,分子对接和分子动力学(MD),以揭示活性所需的3D结构特征。我们的结果表明,基于受体的(Q 2 = 0.603,R 2 ncv = 0.829,R 2 pre = 0.690,SEE = 0.316,SEP = 0.406)和基于配体的3D-QSAR模型(​​Q 2 = 0.506,R 2 ncv = 0.838,R 2 pre = 0.794,SEE = 0.316,SEP = 0.296)是可靠的,具有适当的预测能力。此外,CoMFA,CoMSIA等高线图和MD结果与同源DA受体模型的组合分析表明:(1)D环中的A环,A位置2和R3取代基在设计与更高的活动; (2)拮抗剂的更大的R1取代基(在A环的2位)可能很适合结合口袋。 (3)以MlogP表示的疏水性对于建立令人满意的QSAR模型很重要; (4)结合口袋的关键氨基酸是CYS101,ILE105,LEU106,VAL151,PHE175,PHE184,PRO254和ALA251。据我们所知,这项工作是关于新型融合BAZ作为DA D3拮抗剂的3D-QSAR建模的第一份报告。这些结果可能为更好地理解拮抗作用的机理提供信息,从而有助于设计新的有效DA D3拮抗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号